Synonym
S-12911; S12911; S 12911; S 1291-1; S-1291-1; S1291-1; Strontium Ranelate, trade mane: Protelos or Proto.
IUPAC/Chemical Name
3-Thiopheneacetic acid, 5-(bis(carboxymethyl)amino)-2-carboxy-4-cyano-, strontium salt (1:2)
InChi Key
XXUZFRDUEGQHOV-UHFFFAOYSA-J
InChi Code
InChI=1S/C12H10N2O8S.2Sr/c13-2-6-5(1-7(15)16)10(12(21)22)23-11(6)14(3-8(17)18)4-9(19)20;;/h1,3-4H2,(H,15,16)(H,17,18)(H,19,20)(H,21,22);;/q;2*+2/p-4
SMILES Code
O=C([O-])CC1=C(C([O-])=O)SC(N(CC([O-])=O)CC([O-])=O)=C1C#N.[Sr+2].[Sr+2]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Strontium ranelate can activate the calcium-sensing receptor (CaSR) in non skeletal cells, resulting in the activation of inositol 1, 4, 5-triphosphate production and mitogen-activated protein kinase signaling.
In vitro activity:
This study suggests that strontium ranelate (SR) can accelerate osteoblastic phenotype acquisition, helping to explain the rebalancing of bone turnover in favor of bone formation. SR did not affect MC3TE-E1 cell proliferation and viability at lower concentrations (0.05 and 0.1mM) but decreased them at 0.5mM. SR treatment resulted in higher levels of Type I Collagen and Osteopontin, particularly at 0.5mM. SR also induced fibronectin expression and promoted bone-like nodule formation in a concentration-dependent manner.
Reference: Tissue Cell. 2016 Jun;48(3):183-8. https://pubmed.ncbi.nlm.nih.gov/27157549/
In vivo activity:
SR might be a promising approach for the intervention of fusion-induced adjacent segment disc degeneration (ASDD) with osteoporosis. In a rat a fusion-induced ASDD model, SR exerted a protective effect on adjacent segment intervertebral disc with the underlying mechanism possibly being associated with preserving bone mass to prevent spinal instability, maintaining endplate vascular microstructure functional integrity, and regulating matrix metabolism in the nucleus pulposus and annulus fibrosus.
Reference: Bone Rep. 2024 Feb 15;20:101744. https://pubmed.ncbi.nlm.nih.gov/38404727/
|
Solvent |
mg/mL |
mM |
| Solubility |
| 0.1 M HCL |
17.5 |
34.08 |
| Water |
2.0 |
3.89 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
513.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Ma T, Guan Y, Feng J, Yang Y, Chen J, Guo W, Liao J, Zhang Y. Osteogenic effect of magnesium oxychloride cement modified with phytic acid and loaded with strontium ranelate. Biomater Res. 2023 Dec 10;27(1):128. doi: 10.1186/s40824-023-00474-8. PMID: 38072982; PMCID: PMC10712188.
2. Almeida MM, Nani EP, Teixeira LN, Peruzzo DC, Joly JC, Napimoga MH, Martinez EF. Strontium ranelate increases osteoblast activity. Tissue Cell. 2016 Jun;48(3):183-8. doi: 10.1016/j.tice.2016.03.009. Epub 2016 Apr 16. PMID: 27157549.
3. Sun Q, Liu F, Fang J, Lian Q, Hu Y, Nan X, Tian FM, Zhang G, Qi D, Zhang L, Zhang J, Luo Y, Zhang Z, Zhou Z. Strontium ranelate retards disc degradation and improves endplate and bone micro-architecture in ovariectomized rats with lumbar fusion induced - Adjacent segment disc degeneration. Bone Rep. 2024 Feb 15;20:101744. doi: 10.1016/j.bonr.2024.101744. PMID: 38404727; PMCID: PMC10884424.
4. Xiao X, Cui Y, Lu H, Wang J, Yang J, Liu L, Liu Z, Peng X, Cao H, Liu X, Wei X. Strontium ranelate enriched Ruminococcus albus in the gut microbiome of Sprague-Dawley rats with postmenopausal osteoporosis. BMC Microbiol. 2023 Nov 27;23(1):365. doi: 10.1186/s12866-023-03109-z. PMID: 38008735; PMCID: PMC10680188.
In vitro protocol:
1. Ma T, Guan Y, Feng J, Yang Y, Chen J, Guo W, Liao J, Zhang Y. Osteogenic effect of magnesium oxychloride cement modified with phytic acid and loaded with strontium ranelate. Biomater Res. 2023 Dec 10;27(1):128. doi: 10.1186/s40824-023-00474-8. PMID: 38072982; PMCID: PMC10712188.
2. Almeida MM, Nani EP, Teixeira LN, Peruzzo DC, Joly JC, Napimoga MH, Martinez EF. Strontium ranelate increases osteoblast activity. Tissue Cell. 2016 Jun;48(3):183-8. doi: 10.1016/j.tice.2016.03.009. Epub 2016 Apr 16. PMID: 27157549.
In vivo protocol:
1. Sun Q, Liu F, Fang J, Lian Q, Hu Y, Nan X, Tian FM, Zhang G, Qi D, Zhang L, Zhang J, Luo Y, Zhang Z, Zhou Z. Strontium ranelate retards disc degradation and improves endplate and bone micro-architecture in ovariectomized rats with lumbar fusion induced - Adjacent segment disc degeneration. Bone Rep. 2024 Feb 15;20:101744. doi: 10.1016/j.bonr.2024.101744. PMID: 38404727; PMCID: PMC10884424.
2. Xiao X, Cui Y, Lu H, Wang J, Yang J, Liu L, Liu Z, Peng X, Cao H, Liu X, Wei X. Strontium ranelate enriched Ruminococcus albus in the gut microbiome of Sprague-Dawley rats with postmenopausal osteoporosis. BMC Microbiol. 2023 Nov 27;23(1):365. doi: 10.1186/s12866-023-03109-z. PMID: 38008735; PMCID: PMC10680188.
1: Reginster JY, Brandi ML, Cannata-Andía J, Cooper C, Cortet B, Feron JM, Genant H, Palacios S, Ringe JD, Rizzoli R. The position of strontium ranelate in today's management of osteoporosis. Osteoporos Int. 2015 Jun;26(6):1667-71. doi: 10.1007/s00198-015-3109-y. Epub 2015 Apr 14. Review. PubMed PMID: 25868510.
2: Wang Y, Dai M, Tian F, Zhang L. [Research progress of effects of strontium ranelate on osteoarthritis]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2014 Dec;28(12):1479-83. Review. Chinese. PubMed PMID: 25826890.
3: Vestergaard P. New strategies for osteoporosis patients previously managed with strontium ranelate. Ther Adv Musculoskelet Dis. 2014 Dec;6(6):217-25. doi: 10.1177/1759720X14552070. Review. PubMed PMID: 25435924; PubMed Central PMCID: PMC4239150.
4: Vengerovskiĭ AI, Khlusov IA, Nechaev KA. [Molecular mechanisms of action of bisphosphonates and strontium ranelate]. Eksp Klin Farmakol. 2014;77(9):43-6. Review. Russian. PubMed PMID: 25365870.
5: Bolland MJ, Grey A. A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record. BMJ Open. 2014 Oct 7;4(10):e005787. doi: 10.1136/bmjopen-2014-005787. Review. PubMed PMID: 25293384; PubMed Central PMCID: PMC4187454.
6: Reginster JY. Cardiac concerns associated with strontium ranelate. Expert Opin Drug Saf. 2014 Sep;13(9):1209-13. doi: 10.1517/14740338.2014.939169. Epub 2014 Jul 14. Review. PubMed PMID: 25020233; PubMed Central PMCID: PMC4196504.
7: Tenti S, Cheleschi S, Guidelli GM, Galeazzi M, Fioravanti A. What about strontium ranelate in osteoarthritis? Doubts and securities. Mod Rheumatol. 2014 Nov;24(6):881-4. doi: 10.3109/14397595.2014.888156. Epub 2014 Mar 19. Review. PubMed PMID: 24645726.
8: Khlusov IA, Vengerovsky AI, Novitsky VV. [The combined use of bisphosphonates and strontium ranelate with osseosubstituting materials]. Vestn Ross Akad Med Nauk. 2014;(11-12):128-32. Review. Russian. PubMed PMID: 25971138.
9: Stepan JJ. Strontium ranelate: in search for the mechanism of action. J Bone Miner Metab. 2013 Nov;31(6):606-12. doi: 10.1007/s00774-013-0494-1. Epub 2013 Aug 9. Review. PubMed PMID: 23925392.
10: Przedlacki J. [Strontium ranelate in post-menopausal osteoporosis]. Endokrynol Pol. 2011;62 Suppl 2:23-31. Review. Polish. PubMed PMID: 22125019.
11: García Llopis P, Vicente Valor MI, Martínez Cristóbal A. [Alopecia areata universalis due to strontium ranelate]. Med Clin (Barc). 2012 Mar 3;138(5):229. doi: 10.1016/j.medcli.2011.08.002. Epub 2011 Oct 19. Review. Spanish. PubMed PMID: 22014845.
12: Mentaverri R, Brazier M, Kamel S, Fardellone P. Potential anti-catabolic and anabolic properties of strontium ranelate. Curr Mol Pharmacol. 2012 Jun;5(2):189-94. Review. PubMed PMID: 21787286.
13: Przedlacki J. Strontium ranelate in post-menopausal osteoporosis. Endokrynol Pol. 2011 Jan-Feb;62(1):65-72. Review. PubMed PMID: 21365582.
14: Reginster JY, Neuprez A. Strontium ranelate: a look back at its use for osteoporosis. Expert Opin Pharmacother. 2010 Dec;11(17):2915-27. doi: 10.1517/14656566.2010.533170. Review. PubMed PMID: 21050035.
15: Marie PJ. Strontium ranelate in osteoporosis and beyond: identifying molecular targets in bone cell biology. Mol Interv. 2010 Oct;10(5):305-12. doi: 10.1124/mi.10.5.7. Review. PubMed PMID: 21045244.
16: Gallacher SJ, Dixon T. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int. 2010 Dec;87(6):469-84. doi: 10.1007/s00223-010-9420-x. Epub 2010 Sep 26. Review. PubMed PMID: 20872215.
17: Marie PJ, Felsenberg D, Brandi ML. How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int. 2011 Jun;22(6):1659-67. doi: 10.1007/s00198-010-1369-0. Epub 2010 Sep 2. Review. PubMed PMID: 20812008.
18: Deeks ED, Dhillon S. Spotlight on strontium ranelate: in postmenopausal osteoporosis. Drugs Aging. 2010 Sep 1;27(9):771-3. doi: 10.2165/11206440-000000000-00000. Review. PubMed PMID: 20809666.
19: Hiligsmann M, Vanoverberghe M, Neuprez A, Bruyère O, Reginster JY. Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis. Expert Rev Pharmacoecon Outcomes Res. 2010 Aug;10(4):359-66. doi: 10.1586/erp.10.53. Review. PubMed PMID: 20715911.
20: Ferrari S. Comparing and contrasting the effects of strontium ranelate and other osteoporosis drugs on microarchitecture. Osteoporos Int. 2010 Jun;21 Suppl 2:S437-42. doi: 10.1007/s00198-010-1250-1. Epub 2010 May 13. Review. PubMed PMID: 20464378.
